LBRX
HealthcareLB Pharmaceuticals Inc Common Stock · Biotechnology · $810M
What is LB Pharmaceuticals Inc Common Stock?
LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing new treatments for neuropsychiatric conditions, including schizophrenia and bipolar depression. The company is headquartered in New York and was incorporated in 2025.
LB Pharmaceuticals is working to advance novel drug candidates targeting serious mental health disorders. Its lead program, LB-102, is a methylated derivative of amisulpride, an established antipsychotic compound. The company's business model centers on clinical development — generating value through trial milestones and potential licensing or commercialization of its pipeline, rather than product revenue at this stage.
LB Pharmaceuticals was founded in 2025 and is headquartered in New York, US.
- LB-102 — lead clinical candidate for neuropsychiatric disorders
- Schizophrenia treatment research program
- Bipolar depression therapeutic development
- Methylated amisulpride derivative platform
Is LBRX a Good Stock to Buy?
UQS Score rates LBRX as Poor overall, reflecting the early-stage nature and significant uncertainties common to clinical-stage biotechs.
Among the five pillars, Risk comes in at a Neutral rating — suggesting the company's near-term financial risk profile is not at the extreme end relative to peers at a similar development stage.
Quality, Moat, and Growth all register as Weak, which is typical for a pre-revenue clinical company with no approved products. Valuation is rated Elevated, meaning the current market price reflects considerable optimism about pipeline outcomes.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does LBRX pay dividends?
No — LB Pharmaceuticals Inc Common Stock does not currently pay a dividend.
LBRX does not pay a dividend. As a clinical-stage company with no commercial revenue, LB Pharmaceuticals directs all available capital toward research, clinical trials, and operations. Investors in early-stage biotechs typically seek returns through pipeline progress and potential value creation rather than income distributions.
When does LBRX report earnings?
LB Pharmaceuticals reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly reports focus primarily on cash runway, operating expenses, and clinical trial updates rather than traditional revenue or profit metrics. Pipeline milestones tend to be the most market-moving disclosures.
For the most current quarterly results and pipeline updates, visit LB Pharmaceuticals' investor relations page directly.
LBRX Price History
+101.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
LBRX Long-term Outlook
With Growth and Quality both rated Weak, LBRX's near-term fundamental outlook is heavily dependent on clinical trial outcomes for LB-102. A Neutral Risk rating provides some reassurance that the company is not in immediate financial distress, but an Elevated Valuation suggests the market has already priced in a degree of pipeline success. The path to value creation runs through regulatory and clinical milestones rather than near-term revenue.
Growth drivers
- Advancement of LB-102 through clinical trial phases
- Potential partnership or licensing deals for the amisulpride derivative platform
- Growing unmet need in neuropsychiatric disease treatment
Key risks
- Clinical trial failure or delays for LB-102
- Elevated valuation leaves limited margin of safety if pipeline disappoints
- Dependence on external capital to fund ongoing operations
LBRX vs Peers
LBRX operates in a competitive clinical-stage landscape alongside other small biopharmaceutical companies pursuing specialty therapeutic areas.
MannKind has a commercialized product on the market, giving it a revenue base that distinguishes it from purely clinical-stage peers like LBRX.
Theravance Biopharma focuses on respiratory and other specialty diseases, offering a different therapeutic focus and a more mature pipeline than LBRX.
Alto Neuroscience is also a clinical-stage neuroscience company, making it a close peer to LBRX in terms of development stage and therapeutic focus.
Frequently Asked Questions
What does LB Pharmaceuticals do?
LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases. Its lead candidate, LB-102, targets conditions such as schizophrenia and bipolar depression. The company has no approved products yet and is focused on advancing its pipeline through clinical trials.
Does LBRX pay dividends?
No, LBRX does not pay a dividend. As a pre-revenue clinical-stage company, LB Pharmaceuticals reinvests all available capital into research and development. Investors in this type of company typically look for returns through pipeline progress rather than income.
When does LBRX report earnings?
LB Pharmaceuticals reports on a quarterly cadence, as is standard for US-listed public companies. For the most current earnings dates and results, check the company's investor relations page directly, as our data source does not cover specific upcoming dates.
Is LBRX a good stock to buy?
UQS Score rates LBRX as Poor overall, driven by Weak readings across Quality, Moat, and Growth pillars, alongside an Elevated Valuation. This profile reflects the high uncertainty inherent in clinical-stage biotech investing. The full pillar breakdown is available to UQS Pro members.
Is LBRX overvalued?
The UQS Valuation pillar for LBRX is rated Elevated, suggesting the current market price reflects meaningful optimism about pipeline outcomes. For a pre-revenue company, valuation is particularly sensitive to clinical trial results and investor sentiment around the neuropsychiatric drug space.
How does LBRX compare to its competitors?
LBRX competes in the small-cap clinical-stage biotech space alongside companies like MannKind, Theravance Biopharma, and Alto Neuroscience. Unlike peers with commercial products, LBRX is entirely dependent on its pipeline. UQS Pro members can view side-by-side score comparisons across these companies.
What is LBRX's market cap bracket?
LBRX is classified as a small-cap stock. This is typical for clinical-stage biopharmaceutical companies that have not yet generated commercial revenue, as their market value is largely driven by pipeline potential rather than current earnings.
Who founded LB Pharmaceuticals?
LB Pharmaceuticals was incorporated in 2025. Detailed founding information, including the names of founders and the company's formation history, is publicly available through the company's official disclosures and investor relations materials.
Is LBRX a long-term quality investment?
From a long-term quality standpoint, LBRX's UQS pillars for Quality, Moat, and Growth are all rated Weak — reflecting the absence of revenue, competitive advantages, and a proven business model at this stage. Long-term quality indicators improve as a company advances its pipeline and builds durable fundamentals.
What is the main competitive advantage of LB Pharmaceuticals?
LB Pharmaceuticals' potential differentiation lies in its LB-102 compound, a methylated derivative of an established antipsychotic. If clinical trials demonstrate improved efficacy or tolerability versus existing treatments, this could represent a meaningful advantage — though that outcome remains unproven at this stage.
Unlock Full LBRX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar score breakdown for LBRX
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare LBRX side-by-side with clinical-stage biotech peers
- ✓Screen for higher-quality healthcare stocks using UQS filters
- ✓Get the full analyst-style risk and valuation assessment
Pro Analysis
LBRX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | 15.6 | 0.0 | 9.0 | 18.5 | 64.7 | 0.0 | +6.4 |
| May 9, 2026 | 9.2 | 0.0 | 9.0 | 0.0 | 46.2 | 0.0 | -3.8 |
| Apr 22, 2026 | 13.0 | 0.0 | 9.0 | 18.5 | 47.1 | 0.0 | -0.9 |
| Apr 2, 2026 | 13.9 | 0.0 | 9.0 | 23.1 | 47.1 | 0.0 | — |
LBRX — Pillar Breakdown
Quality
— 0.0/100 (25%)LB Pharmaceuticals Inc Common Stock currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)LB Pharmaceuticals Inc Common Stock faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 64.7/100 (15%)LB Pharmaceuticals Inc Common Stock maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)LB Pharmaceuticals Inc Common Stock appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 9/100 (25%)LB Pharmaceuticals Inc Common Stock operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for LBRX.
Score Composition
Financial Data
More Stock Analysis
How is the LBRX UQS Score Calculated?
The UQS (Unified Quality Score) for LB Pharmaceuticals Inc Common Stock is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses LB Pharmaceuticals Inc Common Stock's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether LB Pharmaceuticals Inc Common Stock is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.